Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer, has expanded its fill-finish services to its Kalamazoo, Michigan (United States), site. Along with vial-filling of small molecules and biologics, the facility also provides vial-filling of sterile suspensions, expanding Pfizer CentreOne’s service portfolio.
“Kalamazoo was the obvious choice for expansion of our fill-finish services,” said Peter Stevenson, Pfizer CentreOne’s Vice President and General Manager. “Our Kalamazoo colleagues have been doing contract manufacturing for over 40 years on the API side – it’s part of the culture; and this is also one of Pfizer’s premier sterile-injectables sites. It’s a natural fit.” With more than 65 years of experience in injectables fill-finish, Kalamazoo currently supplies drugs to more than 100 countries around the globe.
Kalamazoo vial-filling services
Services at the Kalamazoo site encompass:
· Small molecules and biologics
- Sterile suspensions
- Potent and controlled substances
- Aqueous and oil-based formulations
- Vials 1-100mL; bulk formulation <1-1600 liters
The Kalamazoo facility has dedicated, onsite technical, manufacturing science, regulatory affairs and quality teams. Over the last five years, they’ve successfully transferred 37 customer and Pfizer compounds into the facility. Among Kalamazoo’s extensive scientific resources are experts in API processes who know how to solve complex issues with active ingredients; and a team of commodities experts who trouble-shoot problems with stoppers, glass and excipients.
“Our biopharma partners will be in good hands at Kalamazoo,” stated Stevenson, “with a dedicated Pfizer CentreOne team by their side who deeply understand their needs, who can leverage a world of top-flight resources at the site on their behalf.”
Said Bob Betzig, Kalamazoo site head, who oversees all operations on the Kalamazoo campus, “We’re thrilled to expand our contract manufacturing services to include sterile injectables. We value our contract manufacturing partners and pride ourselves on producing difficult-to-make injectables. Our team is ready and waiting.”